Shalin Kothari, MD
Assistant Professor of Medicine (Hematology)DownloadHi-Res Photo
Cards
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Clinician Lead, Cancer Biology Training Program
Core Faculty, Medical Oncology and Hematology Fellowship Program
Contact Info
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Clinician Lead, Cancer Biology Training Program
Core Faculty, Medical Oncology and Hematology Fellowship Program
Contact Info
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Clinician Lead, Cancer Biology Training Program
Core Faculty, Medical Oncology and Hematology Fellowship Program
Contact Info
About
Titles
Assistant Professor of Medicine (Hematology)
Clinician Lead, Cancer Biology Training Program; Core Faculty, Medical Oncology and Hematology Fellowship Program
Biography
Shalin Kothari, MD is an Assistant Professor of Medicine (Hematology) at Yale University. Dr. Kothari completed his residency in Internal Medicine at SUNY Upstate Medical University and his Hematology and Medical Oncology fellowship through the University at Buffalo/Roswell Park Comprehensive Cancer Center where he was the Chief Fellow. He received his Medical Degree from Gujarat University in India.
Dr. Kothari specializes in the treatment of lymphomas. His research is focused on using his clinical skills and basic science knowledge to answer scientific questions focused on mechanistic understanding of lymphoma therapeutics and its translation in the form of early-phase clinical trials for various aggressive forms of B-cell lymphomas including mantle cell lymphoma. He also conducts research in the Müschen Laboratory here at Yale University with a specific focus on developing new therapies for mantle cell lymphoma.
He is a Lymphoma Research Foundation (LRF) Scholar, and an inductee of the ASH Advocacy Leadership Institute and the Gold Humanism Honor Society. He has presented his research in multiple national and international meetings and has won abstract achievement and travel awards.
Appointments
Hematology
Assistant ProfessorPrimary
Other Departments & Organizations
Education & Training
- Fellow
- Roswell Park Comprehensive Cancer Center (2019)
- Internal Medicine Residency
- SUNY Upstate Medical University (2016)
- Senior Research Associate
- University of Louisville (2013)
- MD
- Gujarat University
Research
Overview
Medical Research Interests
Apoptosis; Drug Resistance; Lymphoma, Mantle-Cell
ORCID
0000-0001-9268-0354
Research at a Glance
Yale Co-Authors
Frequent collaborators of Shalin Kothari's published research.
Publications Timeline
A big-picture view of Shalin Kothari's research output by year.
Research Interests
Research topics Shalin Kothari is interested in exploring.
Markus Müschen, MD, PhD
Scott Huntington, MD, MPH, MSc
Tarsheen Sethi, MD, MSc
Kadriye Nehir Cosgun, PhD
Etienne Leveille, MD
Mina Xu, MD
45Publications
247Citations
Lymphoma, Mantle-Cell
Publications
2024
Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation
Epperla N, Huang Y, Cashen A, Vaughn J, Hanel W, Badar T, Barta S, Caimi P, Sethi T, Reddy N, Karmali R, Bello C, Chavez J, Kothari S, Hernandez-Ilizaliturri F, Svoboda J, Lansigan F, Glenn M, Cohen J, Sorge C, Christian B, Herrera A, Hamadani M, Costa L, Xavier A. Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation. Blood Advances 2024, 8: 5458-5466. PMID: 39213424, PMCID: PMC11532746, DOI: 10.1182/bloodadvances.2024013743.Peer-Reviewed Original ResearchConceptsPrimary treatment failureAuto-HCTStable diseaseHodgkin lymphomaPartial responseCumulative incidence of non-relapse mortalityIncidence of non-relapse mortalityAssociated with inferior PFSEfficacy of auto-HCTAssociated with inferior OSAutologous hematopoietic cell transplantationEvaluation of prognostic factorsClassical Hodgkin lymphomaNon-relapse mortalityMulticenter retrospective cohortHigh-risk diseaseHematopoietic cell transplantationLong-term efficacyPatterns of failureUS medical centersProgression of diseaseInferior PFSMedian PFSInferior OSComplete responseHigh-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional series
Epperla N, Zayac A, Landsburg D, Bock A, Nowakowski G, Ayers E, Girton M, Hu M, Beckman A, Li S, Medeiros L, Chang J, Kurt H, Sandoval-Sus J, Ansari-Lari M, Kothari S, Kress A, Xu M, Torka P, Sundaram S, Smith S, Naresh K, Karimi Y, Bond D, Evens A, Naik S, Kamdar M, Haverkos B, Karmali R, Farooq U, Vose J, Rubinstein P, Chaudhry A, Olszewski A. High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional series. Blood Advances 2024, 8: 5355-5364. PMID: 39189932, DOI: 10.1182/bloodadvances.2024013791.Peer-Reviewed Original ResearchAltmetricConceptsBaseline CNS involvementCentral nervous system recurrenceHigh-grade B-cell lymphomaCentral nervous systemB-cell lymphomaCNS involvementCNS recurrenceIncidence of CNS recurrenceRisk of CNS recurrenceCentral nervous system involvementMulti-institutional seriesNon-GCB subtypeBone marrow involvementMulticenter retrospective studyCNS-IPIRisk factor analysisMarrow involvementMYC rearrangementNon-GCBPrimary therapyCD5 expressionAutologous transplantationSurvival outcomesNo significant differenceNOS patientsReal World Data on Efficacy and Safety of EPOCH in T-Cell Lymphoma
Straining R, Foss F, Schiffer M, Amin K, Agarwal S, Isufi I, Huntington S, Kothari S, Seropian S, Girardi M, Sethi T. Real World Data on Efficacy and Safety of EPOCH in T-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2024 PMID: 39368885, DOI: 10.1016/j.clml.2024.09.005.Peer-Reviewed Original ResearchAltmetricConceptsT-cell lymphomaHeterogeneous group of lymphoid malignanciesGroup of lymphoid malignanciesPeripheral T-cell lymphomaAggressive T-cell lymphomaCutaneous T-cell lymphomaT cellsResponse rateR/R settingComplete responseLymphoid malignanciesPoor outcomeAnaplastic large cell lymphomaFrontline treatment regimensLarge cell lymphomaCombination of prednisoneHeterogeneous groupCell lymphomaChemotherapy optionsCaucasian patientsFirst-linePositive patientsTreatment regimensGrade 3LymphomaTuning Responses to Polatuzumab Vedotin in B-cell Lymphoma.
Leveille E, Kothari S, Cosgun K, Mlynarczyk C, Müschen M. Tuning Responses to Polatuzumab Vedotin in B-cell Lymphoma. Cancer Discovery 2024, 14: 1577-1580. PMID: 39228298, DOI: 10.1158/2159-8290.cd-24-0644.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsCharacterizing the authorship of phase 3 randomized clinical trials in oncology, 1960-2023.
Warner J, Bakow B, Brown A, Choe J, Fan E, Ganta T, Glover M, Hadfield M, Hilton C, Khaki A, Kothari S, Lythgoe M, Nagpal S, Nguyen R, Noyd D, Riaz I, Rooney M, Sethi T, Singhi E, Rubinstein S. Characterizing the authorship of phase 3 randomized clinical trials in oncology, 1960-2023. Journal Of Clinical Oncology 2024, 42: 11079-11079. DOI: 10.1200/jco.2024.42.16_suppl.11079.Peer-Reviewed Original ResearchConceptsPhase 3 randomized clinical trialPhase 3 RCTsPrimary endpointClinical trialsEligible publicationsProlific authorsSystemic anticancer therapySuccess rateMann-Whitney U testStandard of carePositive publication biasTrial sample sizePositive resultsYear of publicationPublication biasTherapeutic advancesPrimary outcomeAuthorship patternAnticancer therapyExperimental armAuthor's outputMann-WhitneyU testInterquartile rangeAuthor informationEvaluation of the study of control arms in randomized clinical trials of cancer.
Jain S, Zauderer M, Sethi T, Schoen M, Rubinstein S, Nguyen R, Nagpal S, Mohan S, Madireddy S, Lythgoe M, Liang W, Kulkarni A, Kothari S, Hilal T, Hadfield M, Goyal G, Ganta T, Dholaria B, Brown A, Warner J. Evaluation of the study of control arms in randomized clinical trials of cancer. Journal Of Clinical Oncology 2024, 42: 11023-11023. DOI: 10.1200/jco.2024.42.16_suppl.11023.Peer-Reviewed Original ResearchConceptsRandomized clinical trialsSystemic anti-cancer therapyCancer randomized clinical trialsControl armSuccess rateClinical trials of cancerFisher's exact testAnti-cancer therapyTrial success ratesStudy publication yearExact testPatient convenienceRegimensClinical trialsHighest success rateExperimental armCancer typesCancerContext of treatmentPublication yearTrialsDoseNon-cancerEfficacyDyadsDependence of lymphopoiesis on efficient β-catenin degradation
Cosgun K, Jumaa H, Robinson M, Klemm L, Oulghazi S, Fonseca-Arce D, Xu L, Xiao G, Khanduja D, Chan L, Lee J, Kume K, Song J, Chan W, Chen J, Taketo M, Kothari S. Dependence of lymphopoiesis on efficient β-catenin degradation. The Journal Of Immunology 2024, 212: 1195_4936-1195_4936. DOI: 10.4049/jimmunol.212.supp.1195.4936.Peer-Reviewed Original ResearchConceptsIkaros zinc fingersLymphoid cellsB-cateninChIP-seq analysisSuppression of MYC expressionRegulate lineage specificationInduce cell deathConstitutively low levelsDeletion of ApcChIP-seqTcf factorsZinc fingerProteasomal degradationBinding motifNucleosome remodelingDestruction complexSpecific genesWnt/b-catenin pathwayLineage specificationCell deathMYC expressionSuperenhancersLymphoid developmentEpithelial lineageEpithelial cells
2023
Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma
Gerson J, Handorf E, Villa D, Gerrie A, Chapani P, Li S, Medeiros L, Wang M, Cohen J, Churnetski M, Hill B, Sawalha Y, Hernandez-Ilizaliturri F, Kothari S, Vose J, Bast M, Fenske T, Gari S, Maddocks K, Bond D, Bachanova V, Kolla B, Chavez J, Shah B, Lansigan F, Burns T, Donovan A, Wagner-Johnston N, Messmer M, Mehta A, Anderson J, Reddy N, Kovach A, Landsburg D, Glenn M, Inwards D, Ristow K, Karmali R, Kaplan J, Caimi P, Rajguru S, Evens A, Klein A, Umyarova E, Pulluri B, Amengual J, Lue J, Diefenbach C, Fisher R, Barta S. Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma. Blood Advances 2023, 7: 7393-7401. PMID: 37874912, PMCID: PMC10758713, DOI: 10.1182/bloodadvances.2023010757.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsProgression-free survivalMantle cell lymphomaOverall survivalPleomorphic variantMedian progression-free survivalB-cell non-Hodgkin lymphomaOutcomes of patientsAutologous hematopoietic transplantationNon-Hodgkin lymphomaComplete responsePatient characteristicsPoor prognosisHematopoietic transplantationCell lymphomaSecondary objectiveMonthsPatientsLymphomaSurvivalHigher scoresPrimary objectivePrognosisTransplantationNeoplasmsRepurposing GSK3B Small Molecule Inhibitors for Refractory Lymphoid Malignancies
Cosgun K, Robinson M, Oulghazi S, Xu L, Xiao G, Chan L, Lee J, Kume K, Leveille E, Arce D, Khanduja D, Feldhahn N, Song J, Chan W, Chen J, Taketo M, Schjerven H, Jellusova J, Kothari S, Davids M, Müschen M. Repurposing GSK3B Small Molecule Inhibitors for Refractory Lymphoid Malignancies. Blood 2023, 142: 2818. DOI: 10.1182/blood-2023-190522.Peer-Reviewed Original ResearchConceptsFavorable safety profileSmall molecule inhibitorsT-lymphoid malignancyΒ-catenin degradationLymphoid malignanciesΒ-cateninInteractome studiesSafety profileClinical trialsMolecule inhibitorsLow nanomolar concentrationsΒ-catenin accumulationSolid tumorsRefractory B-cell malignanciesCell deathPK/PD profilesZinc finger proteinRefractory lymphoid malignanciesChIP-seq analysisPhase 2 trialMYC target genesT-cell lymphomaColony formationRapid nuclear accumulationWnt/β-catenin pathwayComputational Discovery and Validation of NAD+ Biosynthesis As Unique Vulnerability in B-Lymphoid Malignancies
Li Q, Robinson M, Leveille E, Zhang C, Sun R, Cheng Z, Kume K, Cosgun K, Kothari S, Khanduja D, Nakada D, Müschen M. Computational Discovery and Validation of NAD+ Biosynthesis As Unique Vulnerability in B-Lymphoid Malignancies. Blood 2023, 142: 418. DOI: 10.1182/blood-2023-190269.Peer-Reviewed Original ResearchConceptsSmall molecule inhibitorsDrug discovery toolNAMPT inhibitorsCompound screenCell type-specific targetsCell linesMolecule inhibitorsPurine/pyrimidine metabolismTumor cell linesEnergy metabolismSalvage biosynthesis pathwaySolid tumor cell linesB cell developmentCellular energy metabolismB cell signalingAmino acid metabolismCell cycle arrestDiscovery toolDepletion of metabolitesBiosynthesis pathwayCompetitive fitnessRate-limiting enzymeNAMPT deletionConditional mouse modelEnergy stress
Clinical Trials
Current Trials
A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies
HIC ID2000036945RolePrincipal InvestigatorPrimary Completion Date07/02/2027Recruiting ParticipantsA Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults With Relapsed/Refractory B-cell Malignancies
HIC ID2000035675RoleSub InvestigatorPrimary Completion Date01/31/2024Recruiting ParticipantsGenderBothAge18+ yearsA Randomized Phase 3 Trial of Continuous vs. Intermittent Maintenance Therapy With Zanubrutinib as Upfront Treatment in Older Patients With Mantle Cell Lymphoma
HIC ID2000036380RolePrincipal InvestigatorPrimary Completion Date08/31/2038Recruiting ParticipantsPhase 2 Study of Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory CD30 Positive T-cell Lymphoma
HIC ID2000029793RoleSub InvestigatorPrimary Completion Date04/30/2028Recruiting ParticipantsPhase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination With Anti-Neoplastic Agents in Subjects With Non-Hodgkin Lymphoma
HIC ID2000032539RoleSub InvestigatorPrimary Completion Date05/19/2029Recruiting Participants
Academic Achievements & Community Involvement
activity Institutional Review Board
CommitteesMemberDetails12/01/2022 - Presentactivity American Society of Hematology
Professional OrganizationsModeratorDetails603. Lymphoid Oncogenesis: Basic: Mechanisms in Lymphomagenesis Symposia: Lymphoid Oncogenesis: Basic Program: Oral and Poster Abstracts Type: Oral Hematology Disease Topics & Pathways: Fundamental Science, Research, Lymphoid Leukemias, ALL, apoptosis, Lymphomas, non-Hodgkin lymphoma, Translational Research, B Cell lymphoma, Genetic Disorders, genomics, T Cell lymphoma, hematopoiesis, Diseases, immune mechanism, aggressive lymphoma, immunology, Lymphoid Malignancies, metabolism, computational biology, Biological Processes, Technology and Procedures, gene editing, molecular biology, Study Population, multi-systemic interactions, Human, pathogenesis, Animal model Monday, December 12, 2022: 10:30 AM-12:00 PM 208-210 (Ernest N. Morial Convention Center) Moderators: Paolo Ghia, MD, PhD, Universita' Vita-Salute San Raffaele C.F. 97187560152 and Shalin K. Kothari, MD, Center of Molecular and Cellular Oncology and Department of Internal Medicine, Section of Hematology, Yale University School of Medicine, New Haven, CT2022 - Presentactivity Clinical Cytometry
Journal ServiceReviewerDetails2018 - Presentactivity Clinical Lymphoma, Myeloma and Leukemia
Journal ServiceReviewerDetails2019 - Presentactivity ASH Advocacy Leadership Institute
Professional OrganizationsMemberDetails2018 - Present
Clinical Care
Overview
Shalin Kothari, MD, is a hematologist who treats patients with Hodgkin and non-Hodgkin lymphoma, including chronic lymphocytic leukemia.
Dr. Kothari’s research focuses on treatments for various aggressive forms of B-cell lymphomas, such as mantle cell lymphomas and diffuse large B-cell lymphomas. This disease causes either circulating lymphoma cells in the blood and/or enlarged lymph nodes due to a rapid accumulation of lymphoma cells.
He is a Lymphoma Research Foundation (LRF) Scholar and an inductee of the ASH Advocacy Leadership Institute and the Gold Humanism Honor Society. Most recently, Dr. Kothari was awarded the Gerald L. Logue Memorial Award for Outstanding Performance in Hematology/Oncology and a research funding award from The DeLuca Center for Innovation in Hematology Research.
Dr. Kothari is an assistant professor of medicine (hematology) at Yale School of Medicine.
Clinical Specialties
Hematology & Oncology; Leukemia & Lymphoma
Fact Sheets
Lymphoma
Learn More on Yale MedicineNon-Hodgkin's Lymphoma
Learn More on Yale MedicineDiffuse Large B-Cell Lymphoma
Learn More on Yale MedicineBlood Clots in Veins, Heart and Lungs
Learn More on Yale Medicine
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileNews
News
- November 14, 2024
Dr. Shalin Kothari NBC CT Interview: What You Should Know About Non-Hodgkins Lymphoma, TV Actor Dave Coulier's cancer diagnosis
- July 13, 2023
Department of Internal Medicine Promotions and Appointments (July 2023)
- September 16, 2019
2019 Department of Internal Medicine Faculty Appointments and Promotions
Get In Touch
Contacts
Appointment Number
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.